Profile

Cover photo
4 followers|3,563 views
AboutPosts

Stream

Agenus Inc.

Shared publicly  - 
 
Agenus Acquires Celexion Assets and Expands Its Antibody Discovery Platform http://bit.ly/1GoGu7q
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN) an immunology company developing innovative treatments for cancers and other diseases, today announced the acquisition of key antibody assets of Celexion, LLC, a privately held Cambridge, Mass. biotech company.
1
George Tong's profile photo
 
Biotech company to watch
Brain tumor vaccine
Add a comment...

Agenus Inc.

Shared publicly  - 
 
Agenus announced today that the Company will present at the Cowen and Company 35th Annual Health Care Conference on Monday, March 2nd at 3:30 p.m. ET. The live and archived webcast of the presentation will be accessible from the Company’s website and will be available for one month following the conference. Read the full press release available here: http://bit.ly/1LEgJhj
1
Add a comment...

Agenus Inc.

Shared publicly  - 
 
Did you know that nearly 70,000 new cases of primary brain tumors will be diagnosed this year? http://bit.ly/1xhhchL #WorldCancerDay
1
Add a comment...

Agenus Inc.

Shared publicly  - 
 
Agenus announced today that the Company will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th at 4:30pm ET. A live webcast of the presentation will be accessible from the Company's website. Read the full press release for additional presentation & webcast information: http://bit.ly/1x8JpHn
1
Add a comment...

Agenus Inc.

Shared publicly  - 
 
The number of shingles cases in Canada are on the rise. http://bit.ly/1CBeBDl
Hundreds of thousands of Canadians each year gets the s ...
1
Add a comment...

Agenus Inc.

Shared publicly  - 
 
Herpes simplex outbreaks usually develop around the mouth or genitals, but the sores can appear almost anywhere on a person's skin. http://bit.ly/1CBed7Y
1
Add a comment...
Have them in circles
4 people
Katherine Johnston's profile photo
Stats A.'s profile photo
William Strivens's profile photo
Erin Schellhammer's profile photo

Agenus Inc.

Shared publicly  - 
 
Agenus today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2014. The company also listed 2014 highlights and target milestones for 2015. Agenus executives will host a conference call today at 11:00 a.m. ET. To access the live call, dial 866-233-4585 (U.S.) or 416-640-5946 (international). A live webcast of the presentation will be accessible from the Company’s website and an archived replay will be available for 60 days. Read the full press release for additional details: http://bit.ly/1LIIjdf
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ:AGEN), an immunology company developing novel therapeutic approaches based on checkpoint modulators (CPMs), heat shock protein-based vaccines, and immune adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2014.
1
Add a comment...

Agenus Inc.

Shared publicly  - 
 
Agenus announced today that the Company will release its fourth quarter and year end 2014 financial results before market opens on Thursday, February 26th, 2015 and host a conference call at 11am ET on the same day. To access the live call dial 866-233-4584 (U.S.) or 416-640-5946 (international). The call will be webcast and accessible from the Company's website. A replay will be available approximately two hours after the call and remain available for 60 days. Read the full press release available here for additional details: http://bit.ly/1AcOAfk
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), will release its fourth quarter and year end 2014 financial results before the market opens on Thursday, February 26, 2015.
1
Add a comment...

Agenus Inc.

Shared publicly  - 
 
Today is World Cancer Day, learn how you can donate and get involved in the fight against brain cancer. http://bit.ly/1xhgili
1
Add a comment...

Agenus Inc.

Shared publicly  - 
 
Glioblastomas (GBM) are tumors that arise from astrocytes cells in the brain. These tumors are usually highly cancerous because the cells reproduce quickly and are supported by a large network of blood vessels. Learn more about GBM from The American Brain Tumor Association: http://bit.ly/1yYR6Bg
Learn about glioblastoma from the American Brain Tumor Association. Discover information on glioblastoma symptoms, treatment, prognosis, causes and more.
1
Add a comment...

Agenus Inc.

Shared publicly  - 
 
Learn your sun safety IQ with a quick quiz from American Cancer Society http://bit.ly/1AKmEiY
1
Add a comment...

Agenus Inc.

Shared publicly  - 
 
When can a cough or headache possibly be something more? Learn cancer symptoms you shouldn't ignore: http://bit.ly/1BLki17
1
Add a comment...
People
Have them in circles
4 people
Katherine Johnston's profile photo
Stats A.'s profile photo
William Strivens's profile photo
Erin Schellhammer's profile photo
Story
Tagline
At Agenus (NASDAQ: AGEN), we believe the best path for treating disease is through activating our own body’s natural mechanisms.
Introduction

For 20 years, Agenus has been focused on building technologies and a product pipeline aimed at treating cancers and infection by helping the body’s immune system to target diseased cells with precision.

We believe in the power of science. The body’s immune system is the single most effective tool we have to protect us from disease and help us fight disease when we get sick. At Agenus, we believe that by activating our body’s own natural mechanisms, using scientifically sound tools, we aim to help the body heal itself.

Our quest for science-focused solutions started in 1994. Nearly 20 years later, we remain committed to delivering on the promise of immunology to treat cancers and infectious diseases.

Agenus is gratified to be part of several important clinical development programs. We’re proud of the deep convictions and commitment we share with our growing circle of partners and collaborators to alleviate the burden of diseases and the burden of treatment.

Pipeline

From advanced programs in late-stage development to our earlier clinical candidates, we continue to advance our groundbreaking technologies and product candidates closer to clinical practice, and closer to delivering on our promise of treating cancers and infectious diseases.

This website contains information regarding our future discovery and development efforts, our collaborations, our operating results and financial position, our business strategy, and other objectives for future operations. This information constitutes a forward-looking statement within the meaning of the Private Securities Litigation Reform Act of 1995. There are a number of risks and uncertainties that could cause our actual results to differ materially from those indicated by such forward-looking statements. These risks and uncertainties include those inherent in pharmaceutical research, such as adverse results in our drug discovery and clinical development processes, decisions made by the FDA and other regulatory authorities with respect to the development and commercialization of our products, and our ability to obtain, maintain and enforce proprietary rights for our products; our dependence on collaborative partners; our ability to obtain any necessary financing to conduct our planned activities, and other risk factors set forth in the filings that we make from time to time with the SEC. We disclaim any intention or obligation to update any forward-looking statements contained on this website, whether as a result of new information, future events or otherwise.